Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis

NCT06825312 is registered in ClinicalTrials.gov with Liaoning Chengda Biotechnology CO., LTD as lead sponsor.

NCT NCT06825312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06825312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis
Lead sponsor
Liaoning Chengda Biotechnology CO., LTD
Phase
Phase 4
Overall status
Active, not recruiting
Start date
November 11, 2023
Completion date
December 31, 2031
Enrollment
600 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

japanese encephalitis vaccine